Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.

4523 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eisai Co., Ltd. is a global, research-based pharmaceutical company founded in 1941. It is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, with a portfolio that includes prescription medicines and over-the-counter drugs. The company operates under its core "human health care" (hhc) philosophy, which prioritizes patients and their families to enhance the benefits provided by healthcare. A key corporate initiative involves improving access to medicines for people in developing and emerging countries, exemplified by its program to supply treatments for lymphatic filariasis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-04 07:00
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 46.9 KB
2025-06-19 09:25
Post-Annual General Meeting Information
臨時報告書
Japanese 31.9 KB
2025-06-13 04:30
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 25.1 KB
2025-06-13 04:29
Registration Form
確認書
Japanese 8.1 KB
2025-06-13 04:28
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 5.2 MB
2025-06-03 08:00
Major Shareholding Notification
変更報告書
Japanese 39.0 KB
2025-05-13 08:00
Major Shareholding Notification
大量保有報告書
Japanese 37.9 KB
2025-05-08 09:00
Regulatory News Service
公開買付報告書
Japanese 41.0 KB
2025-04-01 08:00
M&A Activity
訂正公開買付届出書
Japanese 177.2 KB
2025-03-17 06:00
M&A Activity
公開買付届出書
Japanese 348.4 KB
2025-03-12 07:06
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-12-11 02:14
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.2 KB
2024-11-15 02:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-11-08 06:17
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-08 06:16
Interim Report
半期報告書-第113期(2024/04/01-2025/03/31)
Japanese 268.5 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.